Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. Mammalian target of rapamycin Complex 1 (mTORC1) regulat...

Full description

Bibliographic Details
Main Authors: Jose A. Sandoval, Alexey Tomilov, Sandipan Datta, Sonia Allen, Robert O’Donnell, Thomas Sears, Kevin Woolard, Dmytro Kovalskyy, James M. Angelastro, Gino Cortopassi
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Pharmaceuticals
Subjects:
mTOR
mTORC1
glioblastoma
piperazine
meclizine
Online Access:https://www.mdpi.com/1424-8247/13/12/419

Similar Items

Similar Items